Back

The impact of age on the effectiveness and safety of the NOACs versus warfarin for stroke prevention in atrial fibrillation

28 August 2017 (15:35 - 16:25)
Organised by:
Congress Presentation Part of: Progress in stroke prevention in atrial fibrillation Atrial fibrillation (AF) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Peter Noseworthy

Mayo Clinic, Rochester (United States of America)

6 More presentations in this session

Presentation thumbnail
Adherence to anticoagulant drugs in patients with atrial fibrillation and stroke in real clinical practice
Professor D. Duplyakov (Samara, RU)
Abstract Slides
Presentation thumbnail
Outcomes in vitamin K antagonist treated atrial fibrillation patients with stable international normalized ratios
Doctor A. Nissen Bonde (Roskilde, DK)
Abstract Slides
Presentation thumbnail
Periprocedural anticoagulation is associated with the risk of thromboembolism after elective cardioversion of atrial fibrillation.
Doctor T. Hellman (Turku, FI)
Abstract Slides
Presentation thumbnail
Reduced fibrin clot permeability is associated with an increased risk of both ischemic stroke and major bleeding in atrial fibrillation patients treated with vitamin k antagonists
Professor A. Undas (Krakow, PL)
Abstract Slides
Presentation thumbnail
Use of novel oral anticoagulants in patients with atrial fibrillation and moderate to severe renal dysfunction: findings from a prospective national registry
Professor I. Goldenberg (Rochester, US)
Abstract Slides

Access the full session

Session thumbnail
Progress in stroke prevention in atrial fibrillation

The Event

Event poster

ESC Congress 2017

28 August 2017 15:35 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources